Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Kringle Pharma, Inc. ( (JP:4884) ).
Kringle Pharma, Inc. has announced the establishment of a new subsidiary, Kringle Pharma USA, Inc., to enhance its global footprint and expedite the development of its acute spinal cord injury program in the U.S. market. The subsidiary will be led by Matt Vogelhuber, a seasoned professional in the life sciences industry, and aims to leverage the recent orphan drug designation by the U.S. FDA for Oremepermin alfa to advance clinical development efforts. This strategic move underscores Kringle Pharma’s commitment to innovation and its mission to improve healthcare through HGF-based therapies.
More about Kringle Pharma, Inc.
Kringle Pharma, Inc., founded in December 2001, is a late-stage clinical biopharmaceutical company specializing in innovative biologics based on Hepatocyte Growth Factor (HGF). The company focuses on developing therapies for rare and intractable diseases, with its lead product, Oremepermin alfa, in Phase 3 trials in Japan for treating acute spinal cord injury and vocal cord scarring.
Average Trading Volume: 142,750
Technical Sentiment Signal: Sell
Current Market Cap: Yen3.24B
For detailed information about 4884 stock, go to TipRanks’ Stock Analysis page.